Brief: Synlogic Receives Positive Opinion On Orphan Designation From European Medicines Agency For SYNB1618 For Treatment Of Phenylketonuria
24/05/2022 12:23
May 24 (Reuters) - Synlogic Inc SYBX.O :
* SYNLOGIC RECEIVES POSITIVE OPINION ON ORPHAN DESIGNATION
FROM
THE EUROPEAN MEDICINES AGENCY FOR SYNB1618 FOR THE TREATMENT OF
PHENYLKETONURIA
Source text for Eikon: ID:nGNXbySvBj
Further company coverage: SYBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary